Literature DB >> 16226105

Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.

Yukiko Saitou1, Katsuya Shiraki, Hiroyuki Fuke, Tomoko Inoue, Kazumi Miyashita, Yutaka Yamanaka, Yumi Yamaguchi, Norihik Yamamoto, Keiichi Ito, Kazushi Sugimoto, Takeshi Nakano.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in tumor cells, but not in most normal cells. The role of TRAIL in hepatic cell death and hepatic diseases is not well understood. The present study investigated the expression of TRAIL and TRAIL receptors (TRAIL-Rs) in patients with hepatitis C virus infection using immunohistochemistry and examined physiological roles under viral infection in the HepG2 cell line. Staining of TRAIL or TRAIL-Rs was prominent in the cytoplasm and membrane of hepatocytes in the periportal area. Some liver-infiltrating lymphocytes also displayed positive staining for TRAIL. Staining intensity was significantly increased with disease progression, particularly in the periportal area. AdCMVLacZ (Q-BIOgene, Carisbad, Calif) infection was also found to induce apoptosis in HepG2 cells and significantly augment TRAIL-induced apoptosis. Anti-TRAIL antibody significantly inhibited apoptosis induced by AdCMVLacZ infection. Flow cytometry analysis revealed that both TRAIL-R2 and TRAIL were up-regulated on the cell surface of HepG2 cells with AdCMVLacZ infection. Transforming growth factor-beta1 also enhanced TRAIL expression in HepG2 cells. These results indicate that TRAIL/TRAIL-R apoptotic pathways play important roles in the hepatic cell death during viral infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226105     DOI: 10.1016/j.humpath.2005.07.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon α plus ribavirin: association with viral responses.

Authors:  Derya Seyman; Arzu Didem Yalcin; Nefise Oztoprak; Gizem Esra Genc; Nevgun Sepin Ozen; Filiz Kizilates; Hande Berk; Saadet Gumuslu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

Review 3.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

4.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

Review 5.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 6.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

7.  TRAIL-deficient mice exhibit delayed regression of retinal neovascularization.

Authors:  Kristin E Hubert; Michael H Davies; Andrew J Stempel; Thomas S Griffith; Michael R Powers
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 8.  Following TRAIL's path in the immune system.

Authors:  Christina Falschlehner; Uta Schaefer; Henning Walczak
Journal:  Immunology       Date:  2009-06       Impact factor: 7.397

9.  Hepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathway.

Authors:  Zhongfan Deng; Huijuan Yan; Jiajie Hu; Shengwei Zhang; Peng Peng; Qingzhen Liu; Deyin Guo
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

10.  NK cells: a double-edged sword in chronic hepatitis B virus infection.

Authors:  Mala K Maini; Dimitra Peppa
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.